Researchers design first battery-powered invisibility cloak.


Researchers at The University of Texas at Austin have proposed the first design of a cloaking device that uses an external source of energy to significantly broaden its bandwidth of operation.

Andrea Alù, associate professor at the Cockrell School of Engineering, and his team have proposed a design for an active cloak that draws energy from a battery, allowing objects to become undetectable to radio sensors over a greater range of frequencies.

The team’s paper, “Broadening the Cloaking Bandwidth with Non-Foster Metasurfaces,” was published Dec. 3 in Physical Review Letters. Alù, researcher Pai-Yen Chen and postdoctoral research fellow Christos Argyropoulos co-authored the paper. Both Chen and Argyropoulos were at UT Austin at the time this research was conducted. The proposed active cloak will have a number of applications beyond camouflaging, such as improving cellular and radio communications, and biomedical sensing.

Cloaks have so far been realized with so-called passive technology, which means that they are not designed to draw energy from an external source. They are typically based on metamaterials (advanced artificial materials) or metasurfaces (a flexible, ultrathin metamaterial) that can suppress the scattering of light that bounces off an object, making an object less visible. When the scattered fields from the cloak and the object interfere, they cancel each other out, and the overall effect is transparency to radio-wave detectors. They can suppress 100 times or more the detectability at specific design frequencies. Although the proposed design works for radio waves, active cloaks could one day be designed to make detection by the human eye more difficult.

“Many cloaking designs are good at suppressing the visibility under certain conditions, but they are inherently limited to work for specific colors of light or specific frequencies of operation,” said Alù, David & Doris Lybarger Endowed Faculty Fellow in the Department of Electrical and Computer Engineering. In this paper, on the contrary, “we prove that cloaks can become broadband, pushing this technology far beyond current limits of passive cloaks. I believe that our design helps us understand the fundamental challenges of suppressing the scattering of various objects at multiple wavelengths and shows a realistic path to overcome them.”

The proposed active cloak uses a battery, circuits and amplifiers to boost signals, which makes possible the reduction of scattering over a greater range of frequencies. This design, which covers a very broad frequency range, will provide the most broadband and robust performance of a cloak to date. Additionally, the proposed active technology can be thinner and less conspicuous than conventional cloaks.

In a related paper, published in Physical Review X in October, Alù and his graduate student Francesco Monticone proved that existing passive cloaking solutions are fundamentally limited in the bandwidth of operation and cannot provide broadband cloaking. When viewed at certain frequencies, passively cloaked objects may indeed become transparent, but if illuminated with white light, which is composed of many colors, they are bound to become more visible with the cloak than without. The October paper proves that all available cloaking techniques based on passive cloaks are constrained by Foster’s theorem, which limits their overall ability to cancel the scattering across a broad frequency spectrum.

In contrast, an active cloak based on active metasurfaces, such as the one designed by Alù’s team, can break Foster’s theorem limitations. The team started with a passive metasurface made from an array of metal square patches and loaded it with properly positioned operational amplifiers that use the energy drawn from a battery to broaden the bandwidth.

https://i0.wp.com/cdn.physorg.com/newman/gfx/news/2013/dthtynh.jpg

“In our case, by introducing these suitable amplifiers along the cloaking surface, we can break the fundamental limits of passive cloaks and realize a ‘non-Foster’ surface reactance that decreases, rather than increases, with frequency, significantly broadening the of operation,” Alù said.

The researchers are continuing to work both on the theory and design behind their non-Foster active cloak, and they plan to build a prototype.

Alù and his team are working to use active cloaks to improve wireless communications by suppressing the disturbance that neighboring antennas produce on transmitting and receiving antennas. They have also proposed to use these cloaks to improve biomedical sensing, near-field imaging and energy harvesting devices.

FDA Approves Anoro Ellipta to Treat COPD


A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration.

GlaxoSmithKline‘s Anoro Ellipta is meant to be used once a day for long-term maintenance of airflow in patients with COPD. The lung disease makes breathing difficult and worsens over time.

“Anoro Ellipta works by helping the muscles around the airways of the lungs stay relaxed to increase airflow in patients with COPD,” Dr. Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research, said in an agency news release.

“The availability of new long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD,” he added.

Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, said the new medication is a “unique combination” of two drugs presently used for COPD. “It combines a drug similar to Spiriva and a [long-acting beta agonist] as found in Advair, he said. “There is no steroid in Anoro Ellipta.”

According to the FDA, Anoro Ellipta combines umeclidinium, a drug that prevents muscles around the large airways from tightening, and vilanterol, which improves breathing by relaxing the muscles of the airways to allow more air to flow into and out of the lungs.

Another lung specialist, Dr. Charles Powell, called the approval a “promising development for patients with COPD,” noting other countries already allow this type of medication.

“Combined long-acting bronchodilators are available in Europe. Now we have the first approved combined long-acting bronchodilator medication available in the U.S.,” said Powell, who is chief of pulmonary, critical care and sleep medicine at the Mount Sinai – National Jewish Health Respiratory Institute in New York City.

“Combining two effective bronchodilators can result in improved lung function and medication compliance compared to traditional COPD inhaled medications,” Powell said.

The FDA approval is based on findings from more than 2,400 people with COPD. The results showed that those who took the drug had greater improvements in lung function than those who took a placebo. The most common side effects reported by patients who took Anoro Ellipta included sore throat, sinus infection, lower respiratory tract infection, constipation, diarrhea, pain in extremities, muscle spasms, neck pain and chest pain.

Serious side effects that can be caused by the drug include narrowing and obstruction of the airway, cardiovascular effects, increased pressure in the eyes, and worsening of urinary retention.

Anoro Ellipta is not approved for asthma treatment and should not be used as a rescue treatment for sudden breathing problems, the FDA said. The drug carries a boxed warning that the class of drugs that vilanterol belongs to increases the risk of asthma-related death.

“Patients with COPD need to be seen and examined before determining the appropriate use of this drug, as with any medication,” added Horovitz.

Cigarette smoking is the main contributor to COPD, which is the third leading cause of death in the United States. Symptoms can include chest tightness, chronic cough and excessive phlegm.

Water geysers erupt on Europa! Could Jupiter’s icy moon host life?


Jupiter’s icy moon Europa squirts water like a squishy bath toy when it’s squeezed by the gas giant’s gravity, scientists say. Using NASA’s Hubble Space Telescope, they caught two 124-mile-tall geysers of water vapor spewing out over seven hours from near its south pole.

Water on Jupiter's moon Europa

The discovery, described in the journal Science and at the American Geophysical Union meeting in San Francisco, shows that Europa is still geophysically active – and that this world in our own solar system could hold an environment friendly to life.

“It’s exciting,” said Lorenz Roth, a planetary scientist at the Southwest Research Institute in San Antonio and one of the study’s lead authors. “The results are actually more convincing than I would have thought before.”

Europa isn’t the only squirty moon in our planetary system: Saturn’s moon Enceladus has also been caught shooting water out of its south pole in so-called tiger stripes. These pretty plumes are caused by tidal forces. Just as our moon’s gravity squeezes and stretches the Earth a bit, causing the oceans to rise and fall, Saturn’s massive gravitational pull squeezes and stretches its tiny moon, causing cracks on its icy surface to open and allowing water to shoot out.

Scientists have long wondered whether something similar was happening on Jupiter’s moon Europa. After all, its surface is about 65 million years old, which is extremely young by our solar system’s standards, little more than 1.5% of the solar system’s age. This should mean that some geophysical processes must be constantly renewing the surface.

But over several decades, researchers repeatedly failed to catch the moon in action, said Robert Pappalardo, a Jet Propulsion Laboratory planetary scientist who was not involved in the study.

When the Voyager spacecraft, launched in 1977, flew by Europa, it caught a tiny blip on the moon’s edge that people thought might be a plume, but it could not be confirmed. Then the 1989 Galileo spacecraft saw a potential plume of its own. But this turned out to be digital residue, traces of a previous image, Pappalardo said.

Even Hubble probably wasn’t able to properly see such plumes until space shuttle astronauts on the very last servicing mission for the iconic space telescope in 2009 fixed one of its cameras. Even now, looking for water vapor in the ultraviolet wavelengths of light tests the limits of Hubble’s abilities, scientists said.

To catch Europa in the act, the researchers also knew they had to time their observations right. Saturn’s icy moon, Enceladus, shoots water near the farthest point in its orbit from Saturn, when the tidal forces cause cracks at the moon’s south pole to open. Around Jupiter, Europa was probably doing the same thing.

Sure enough, when the scientists looked at Europa when it was close to Jupiter in its orbit, they saw nothing. But in December 2012, when the ice moon was at its farthest point from the gas giant, they caught a pair of plumes bearing clear signs of oxygen and hydrogen – the components of water vapor – shooting from near the southern pole.

Scientists can’t say exactly where the plumes are coming from. It could be that they’re going directly from solid ice to gas, as Europa’s ice sheets rub against each other. But it could also be that the these plumes of vapor may be coming from the ocean of liquid water thought to lie under the moon’s frozen surface.

If the moon is still geophysically active, that could make it a prime environment for life.

Another study out of this week’s American Geophysical Union meeting found signs of clays on Europa’s surface. Clays are often associated with organic matter, which is why NASA’s Mars rover Curiosity is headed to Mt. Sharp, whose clay-rich layers could hold signs of life-friendly environments.

Those clays were probably brought to Europa by comets or asteroids, and if such material was able to make it into Europa’s subsurface ocean, it could provide the nutrient-rich soup that could allow life to emerge.

“We’re trying to understand, could this be a habitable environment today? Could there be life there today?” Pappalardo said. “At Europa, it seems the processes that could permit habitability may be going on now.”

Perhaps future studies can analyze all the contents of that watery plume and see if there are any signs of organic matter, Pappalardo said. Perhaps a future mission to Europa could fly through the plume and directly sample its contents.

For now, it’s important to replicate the results, he added.

“I will sleep better knowing that there are follow-up observations that confirm it,” Pappalardo said.

Intravenous Ozone Therapy Offers Help for All.


Wouldn’t it be great if there were a natural medicine that safely destroyed every bacteria, fungus, yeast and mold with virtually no adverse reaction? And what if it also destroyed every toxin, harmful free radical, and parasite in the body safely as well? One such treatment does exist and has been used by thousands of physicians in over 45 countries for over 70 years.

Screen-shot-2012-09-30-at-11.46.00-AM

Intravenous Ozone Therapy treatment consists of the use of medical grade oxygen and ozone gases safely injected into the vein. The extra “O” in the ozone molecule acts like a glue stealing an electron from anything in the body that it can latch onto. Healthy cells, which contain antioxidants, are not impacted but all pathogens are destroyed.

Despite its effectiveness in studies published on OzoneUniversity.com and the National Library of Medicine (PubMed.gov), thistherapy is not well known. Dr. Howard Robins, DPM, explains, “It may be hard to believe but the pharmaceutical industry along with the FDA has suppressed information and its use here in the USA, along with state health departments, because of the money that would be lost if the use of antibiotics, antivirals and antifungal medicines were diminished due to the amazing benefits of this treatment.”

“If you have a disease or condition that you haven’t been able to get rid of, Ozone Therapy will most likely be the answer, even for people that have suffered for years and have lost all hope,” says Robins.

New Recommendations for Hypertension Management Released.


New recommendations published online in the Journal of the American Medical AssociationExternal Link aim to provide guidance on the management of patients with hypertension. More specifically, the recommendations focus on when medication should be started in patients, the best choices for medications to begin treatment; and communicating achievable blood pressure goals to patients.

“Patients want to be assured that blood pressure (BP) treatment will reduce their disease burden, while clinicians want guidance on hypertension management using the best scientific evidence. This report takes a rigorous, evidence-based approach to recommend treatment thresholds, goals, and medications in the management of hypertension in adults,” the report authors note.

The report, written by panel members appointed to the Eighth Joint National Committee, notes there is strong evidence to support treating hypertensive persons aged 60 years or older to a BP goal of less than 150/90 mm Hg and hypertensive persons 30 through 59 years of age to a diastolic goal of less than 90 mm Hg. However, given insufficient evidence in hypertensive persons younger than 60 years for a systolic goal, or in those younger than 30 years for a diastolic goal, the panel recommends a BP of less than 140/90 mm Hg for those groups. “The same thresholds and goals are recommended for hypertensive adults with diabetes or nondiabetic chronic kidney disease (CKD) as for the general hypertensive population younger than 60 years,” the report notes.

In general, the report authors note that the 140/90 mm Hg definition from Joint National Committee 7 “remains reasonable” and recommend that lifestyle interventions be used for everyone with blood pressures in this range. “For all persons with hypertension, the potential benefits of a healthy diet, weight control, and regular exercise cannot be overemphasized,” they said. “These lifestyle treatments have the potential to improve BP control and even reduce medication needs.”

Also in the report, the authors note there is moderate evidence to support initiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, or thiazide-type diuretic in the nonblack hypertensive population, including those with diabetes. In the black hypertensive population, including those with diabetes, a calcium channel blocker or thiazide-type diuretic is recommended as initial therapy. Additionally, there is moderate evidence to support initial or add-on antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to improve kidney outcomes.

Moving forward, the authors point out that an algorithm included as part of the recommendations will facilitate implementation and be useful to busy clinicians. They also suggest that “the strong evidence base of this report be used to inform quality measures for the treatment of patients with hypertension.”

Practice guidelines are traditionally promulgated by the government or by learned medical professional societies. The JAMA paper is a report of a group experts in the field of hypertension, but it does not carry the endorsement of any organized body. Moving forward, these recommendations will be taken into account in the coming year as the ACC/AHA Task Force on Practice Guidelines moves forward with developing the collaborative model to update the national hypertension guidelines in partnership with the National Heart, Lung, and Blood Institute (NHLBI). According to the ACC and the American Heart Association (AHA), once a writing group is appointed, there will be an extensive science and evidence review process, followed by draft recommendations that will undergo a peer and stakeholder review. Once the review process is complete, the ACC/AHA and partnering organizations will publish the guidelines in 2015 for clinicians to follow as the national standard for hypertension prevention and treatment.

The ACC, AHA and the Centers for Disease Control and Prevention released a scientific advisory on the effective approach to hypertension in November that encourages use of enhanced, evidence-based, blood pressure treatment systems for providers, including standardization of protocols and algorithms, incentives for improved performance based on achieving and maintaining patients at blood pressure goals, and technology-facilitated clinical decision support and feedback.

Academics should not remain silent on hacking : Nature News & Comment


Academics should not remain silent on hacking

The revelation that US and British spy agencies have undermined a commonly used encryption code should alarm researchers, says Charles Arthur.

Secrecy doesn’t come naturally to journalists, but sometimes it is thrust upon us. Earlier this year, there was a room in The Guardian‘s offices in London that nobody could enter alone. On a table outside by a security guard was a tidy collection of phones and other devices; nothing electronic was allowed. Inside were a coffee maker, a shredder, some paper and a few computers. All were brand new; none had ever been connected to the Internet. None ran Microsoft Windows. All were encrypted; each required two passwords, held by different people.

This is where the biggest news stories of this year lived — away from the Internet. This was where The Guardian analysed the ‘Snowden files’ (classified documents released to the press by former US National Security Agency (NSA) contractor Edward Snowden). These revealed, among other things, that the NSA and the United Kingdom’s GCHQ were running enormous efforts to crack encrypted communications online, and that they had worked to undermine the strength of encryption standards such as that used — and recommended — by the US National Institute of Standards and Technology (NIST). (The computers sadly are no more — smashed in The Guardian basement on the orders of the British government.)

NIST’s standard for random numbers used for cryptography, published in 2006, had been weakened by the NSA. Companies such as banks and financial institutions that rely on encryption to guarantee customer privacy depend on this standard. The nature of the subversions sounds abstruse: the random-number generator, the ‘Dual EC DRBG‘ standard, had been hacked by the NSA so that its output would not be as random as it should have been. That might not sound like much, but if you are trying to break an encrypted message, the knowledge that it is hundreds or thousands of times weaker than advertised is a great encouragement.

It was, to be frank, a big deal. In the world’s universities, computer scientists and mathematicians spend their careers trying to develop secure systems, and yet here was evidence of a systematic — and successful — attempt to undermine that work. Executives at companies such as Google, Yahoo, Facebook and Microsoft, which discovered that their internal networks were being tapped and their systems infiltrated, were furious. But a few isolated shouts of protest aside, the academic community has largely been silent.

That’s disappointing. Academia is where we expect to hear the free flow of ideas and opinions. Yet it has been the commercial companies that have made the most noise — because the revelations threaten trust in their businesses. Don’t academics also see the threat to open expression, and to the flow of dissident ideas from countries where people might fear that their communications are being tapped and, even if encrypted, cracked?

“Academics in cryptography and security should make themselves a promise: ‘we won’t get fooled again.’”

Some get it. Ross Anderson, a security researcher at the University of Cambridge, UK, has been highly critical and outspoken. When I spoke to him in September, soon after the NIST revelation, he called it “a wake-up call for a lot of people” and added: “This has been a 9/11 moment for the community, and it’s great that some people are beginning to wake up.”

Kenneth White, principal scientist at health-information company Social & Scientific Systems in Silver Spring, Maryland, says: “Just a year ago, such a story would have been derogated by most of my colleagues as unwarranted suspicion at best and outright paranoia at worst. But here we are.”

Anderson has an explanation for the muted response: he says that a number of British university departments have been quietly coerced by the GCHQ. The intelligence-gathering agency has a substantial budget, and ropes in academics by offering access to funds that ensures their silence on sensitive matters, Anderson says. (If that sounds like paranoia, then see above.)

I have not been able to confirm his claims, but what are the alternatives? One is that the academics are simply too busy going back over their own work looking to see if they agree with the claimed weaknesses. The other is that they simply don’t care enough.

For those who do care, White and Matthew Green, who teaches cryptography at Johns Hopkins University in Baltimore, Maryland, have embarked on an ambitious effort to clean up the mess — one that needs help.

They have created a non-profit organization called OpenAudit.org, which aims to recruit experts to provide technical assistance for security projects in the public interest, especially open-source security software. A similar effort initiated by White and Green is checking the open-source software called TrueCrypt, which is widely used to lock down hard drives during foreign travel (see go.nature.com/nsvdjh).

Concerns over the security of the NIST Dual EC DRBG standard were raised in 2007, but too few academics spoke out then. The events of 2013 must make them rethink. Cryptography rarely reaches the headlines, but now it has done so for all the wrong reasons. For 2014, academics working in cryptography and security should make themselves a promise: ‘We won’t get fooled again.’ And most of all, ‘We won’t go down quietly.’

Smoking Injurious to Genes Too


Here comes another shocker for those reluctant to kick the butt.

Smoking not only affects your health but also increases health risks of your children and grandchildren; today’s puffs of pleasure can permanently damage your genes, according to a new study.

Smoking can also affect the genes important for sperm quality or immune response.

The research findings from Uppsala University and Uppsala Clinical Research Center of Sweden showed that smoking alters several genes that can be associated with health problems for smokers, such as increased risk for cancer and diabetes.

The research, led by Asa Johansson, researcher at the Department of Immunology, Genetics and Pathology, said the genes of smokers as well tobacco users can change and expose them to more health risks.

However, according to the findings, tobacco itself may not be the cause of gene alterations, but the different elements that are formed when the tobacco is burnt.

“Our results therefore indicate that the increased disease risk associated with smoking is partly caused by epigenetic changes. A better understanding of the molecular mechanism behind diseases and reduced body function might lead to improved drugs and therapies in the future,” Johansson said.

The findings of the study have been published in the journal Human Molecular Genetics.

Apple-a-day call for all over-50s


apple

 

If everyone over the age of 50 ate an apple a day, 8,500 deaths from heart attacks and strokes could be avoided every year in the UK, say researchers.

 

Apples would give a similar boost to cardiovascular health as medicines, such as statins, yet carry none of the side-effects, the University of Oxford researchers say in the BMJ.

 

They base their assumptions on modelling, not direct scientific study.

 

Any fruit should work, but getting people to comply could be challenging.

 

“Start Quote

It just shows how effective small changes in diet can be, and that both drugs and healthier living can make a real difference in preventing heart disease and stroke.”

Dr Adam Briggs Lead researcher

 

More than two-thirds of adults do not eat the recommended five portions of fruit and veg a day, population surveys suggest.

 

And although nine in 10 of us do manage to eat at least one portion a day, Dr Adam Briggs and colleagues, from the British Heart Foundation Health Promotion Research Group at Oxford University, say we would all benefit from eating more.

 

By their calculations, if adults of all ages could manage to eat an extra portion of fruit or veg a day, as many as 11,000 vascular deaths could be averted each year.

 

Nutritional composition of an apple

apple
  • Energy: 35.4kcal
  • Fat: 0.09g
  • Saturated fat: 0.02g
  • Monosaturates: 0.01g
  • Polyunsaturates: 0.05g
  • Cholesterol: 0.00mg
  • Fibre: 1.39g
  • Salt: 0.00g

 

The Victorian mantra of “an apple a day” to keep the doctor away is particularly important for the over-50s, who are at increased risk of vascular diseases, say the researchers.

 

They analysed the effect on the most common causes of vascular mortality – heart attacks and strokes – of prescribing either a statin a day, which lowers cholesterol, or an apple a day to people over 50.

 

Assuming at least seven in every 10 complied with the advice, statin drugs could save 9,400 lives and an apple a day 8,500 lives a year, they calculate.

 

The data their work rests on comprises a large body of medical trials and observations involving hundreds of thousands of patients.

 

Dr Briggs said: “The Victorians had it about right when they came up with their brilliantly clear and simple public health advice, ‘An apple a day keeps the doctor away’

 

“It just shows how effective small changes in diet can be, and that both drugs and healthier living can make a real difference in preventing heart disease and stroke.

 

“While no-one currently prescribed statins should replace them for apples, we could all benefit from simply eating more fruit.”

 

Dr Peter Coleman, of the Stroke Association, said everyone stood to benefit from eating a balanced diet.

 

“Apples have long been known as a natural source of antioxidants and chemical compounds called flavanoids, all of which are good for our health and wellbeing.

 

“This study shows that, as part of a healthy diet with plenty of fresh fruit and veg, a daily apple could help to reduce the risk of stroke and heart disease. “

Pesticides may harm growing brains


bees
Several research papers have indicated that neonicotinoid chemicals have an adverse impact on bees

Two neonicotinoid chemicals may affect the developing nervous system in humans, according to the EU.

The European Food Safety Authority (EFSA) proposed that safe levels for exposure be lowered while further research is carried out.

They based their decision on studies that showed the chemicals had an impact on the brains of newborn rats.

One of the pesticides was banned in the EU last April amid concerns over its impact on bee populations.

Neonicotinoids are “systemic” pesticides that make every part of a plant toxic to predators.

They have become very popular across the world over the past two decades as they are considered less harmful to humans and the environment than older chemicals.

But a growing number of research papers have linked the use of these nicotine-like pesticides to a rapid fall in bee numbers.

New levels needed

In April, the European Union introduced a two year moratorium on the use of several types of these chemicals, despite opposition from the UK.

Now EFSA, in a statement, says that it has concerns that two types of neonicotinoids, imidacloprid and acetamiprid, may “affect the developing human nervous system”.

They have proposed that guidance levels for acceptable exposure be lowered while further research is carried out.

The decision has been based on a review of research carried out in rats.

In one study, young rodents exposed to imidacloprid suffered brain shrinkage, weight loss and reduced movement.

In the statement, EFSA said that the two neonicotinoids may “adversely affect the development of neurons and brain structures associated with functions such as learning and memory”.

Current guidelines, it went on, “may not be protective enough to protect against developmental neurotoxicity and should be reduced”.

According to EU Commission health spokesman Frederic Vincent, they would now allow the chemical companies involved to comment on the findings.

“In principle, the next step would then be to amend the reference values,” he said, indicating that this would begin next March.

In their findings, EFSA pointed out that the available evidence had limitations but that they believed the health concerns that have been raised are legitimate.

But other experts said the move by EFSA was more of a precaution than anything else.

“The reduction in the reference values in most cases was modest,” said Prof Alan Boobis, from Imperial College London.

“Whilst there is clearly a question mark over the possible effects of these compounds on the developing brain, the conclusions of EFSA do not suggest that exposure of humans to these compounds at the levels that occur normally in food or in the environment is a cause for concern.”

Scientists ‘print’ new eye cells


human eye
Many teams are researching different ways to repair the sight-giving cells of the retina

Scientists say they have been able to successfully print new eye cells that could be used to treat sight loss.

The proof-of-principle work in the journal Biofabrication was carried out using animal cells.

The Cambridge University team says it paves the way for grow-your-own therapies for people with damage to the light-sensitive layer of tissue at back of the eye – the retina.

More tests are needed before human trials can begin.

“Start Quote

This is a step in the right direction as the retina is often affected in many of the common eye conditions, causing loss of central vision which stops people watching TV and seeing the faces of loved ones”

Clara Eaglen of the RNIB

At the moment the results are preliminary and show that an inkjet printer can be used to print two types of cells from the retina of adult rats―ganglion cells and glial cells.

These are the cells that transmit information from the eye to certain parts of the brain, and provide support and protection for neurons.

The printed cells remained healthy and retained their ability to survive and grow in culture.

Retinal repair

Co-authors of the study Prof Keith Martin and Dr Barbara Lorber, from the John van Geest Centre for Brain Repair at the University of Cambridge, said: “The loss of nerve cells in the retina is a feature of many blinding eye diseases. The retina is an exquisitely organised structure where the precise arrangement of cells in relation to one another is critical for effective visual function.

Human eye
The retina sits at the back of the eye

“Our study has shown, for the first time, that cells derived from the mature central nervous system, the eye, can be printed using a piezoelectric inkjet printer. Although our results are preliminary and much more work is still required, the aim is to develop this technology for use in retinal repair in the future.”

They now plan to attempt to print other types of retinal cells, including the light-sensitive photoreceptors – rods and cones.

Scientists have already been able to reverse blindness in mice using stem cell transplants.

And there is promising work into electronic retina implants implants in patients.

Clara Eaglen, of the RNIB, said: “Clearly it’s still at a very early stage and further research is needed to develop this technology for use in repairing the retina in humans.

“The key to this research, once the technology has moved on, will be how much useful vision is restored.

“Even a small bit of sight can make a real difference, for some people it could be the difference between leaving the house on their own or not.

“It could help boost people’s confidence and in turn their independence.”

Prof Jim Bainbridge of London’s Moorfields Eye Hospital said: “The finding that eye cells can survive the printing process suggests the exciting possibility that this technique could be used in the future to create organised tissues for regeneration of the eye and restoration of sight.

“Blindness is commonly caused by degeneration of nerve cells in the eye. In recent years there has been substantial progress towards the development of new treatments involving cell transplantation.”